Performance of a population-based HIV-1 tropism phenotypic assay and correlation with V3 genotypic prediction tools in recent HIV-1 seroconverters

Journal of Acquired Immune Deficiency Syndromes

Volumn 48, Issue 3, 2008, Pages 241-244

  De Mendoza, Carmen ^a   Van Baelen, Kurt ^b   Poveda, Eva ^a   Rondelez, Evelien ^b   Zahonero, Natalia ^a   Stuyver, Lieven ^b   Garrido, Carolina ^a   Villacian, Jorge ^b   Soriano, Vincent ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b Virco BVBA   (Belgium)

Author keywords

CCR5 antagonists; Drug resistance; HIV; Seroconversion; Tropism

Indexed keywords

CHEMOKINE RECEPTOR CCR5 ANTAGONIST; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA; VIRUS ENVELOPE PROTEIN;

ARTICLE; CD4 LYMPHOCYTE COUNT; ENVELOPE GENE; FEMALE; GENE SEQUENCE; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; SEROCONVERSION; VIROGENESIS; VIRUS LOAD; ADULT; EVALUATION; GENETIC PROCEDURES; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PLANT GROWTH; SENSITIVITY AND SPECIFICITY; VIRUS GENE;

ADULT; CD4 LYMPHOCYTE COUNT; FEMALE; GENES, VIRAL; GENETIC TECHNIQUES; GENOTYPE; HIV SEROPOSITIVITY; HIV-1; HUMANS; MALE; PHENOTYPE; SENSITIVITY AND SPECIFICITY; TROPISM; VIRAL ENVELOPE PROTEINS; VIRAL LOAD;

EID: 47049096112     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181734f0e     Document Type: Article

References (29)

1. Fatkenheuer G, Pozniak A, Jonson M, et al. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat Med. 2005;11:1170-1172.
2. Gulick R, Su Z, Flexner C, et al. Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-infected, treatment-experienced patients: AIDS Clinical Trials Group 5211. J Infect Dis. 2007;196:304-312.
3. Berger E, Murphy P, Farber J. Chemokine receptors as HIV-1 coreceptors: role in viral entry, tropism, and disease. Annu Rev Immunol. 1999;17:657-700.
4. Brumme Z, Goodrich J, Mayer H, et al. Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral naïve individuals. J Infect Dis. 2005;192:466-474.
5. Moyle G, Wildfire A, Mandalia S, et al. Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection. J Infect Dis. 2005; 91:866-872.
6. Poveda E, Briz V, Quiñónes-Mateu M, et al. HIV tropism: diagnostic tools and implications for disease progression and treatment with entry inhibitors. AIDS. 2006;20:1359-1367.
7. Johnson V, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: 2007. Top HIV Med. 2007;15:119-125.
8. de Mendoza C, Rodriguez C, Garcia F, et al. Prevalence of X4 tropic viruses in patients recently infected with HIV-1 and lack of association with transmission of drug resistance. J Antimicrob Chemother. 2007;59: 698-704.
9. de Mendoza C, Rodriguez C, Colomina J, et al. Resistance to nonnucleoside reverse transcriptase inhibitors and prevalence of HIV type 1 non-B subtypes are increasing among persons with recent infection in Spain. Clin Infect Dis. 2005;41:1350-1354.
10. Van Baelen K, Vandenbroucke I, Rondelez E, et al. HIV-1 coreceptor usage determination in clinical isolates using clonal and population-based genotypic and phenotypic assays. J Virol Methods. 2007;146:61-73.
11. Poveda E, Briz V, de Mendoza C, et al. Prevalence of X4 tropic HIV-1 variants in patients with differences in disease stage and exposure to antiretroviral therapy. J Med Virol. 2007;79:1040-1046.
12. Pillai S, Good B, Richman D, et al. A new perspective on V3 phenotype prediction. AIDS Res Hum Retroviruses. 2003;19:145-149.
13. Jensen M, Li F, van't Wout A, et al. Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of HIV type 1 env V3 loop sequences. J Virol. 2003;77:13376-13388.
14. Jensen M, Coetzer M, van't Wout A, et al. A reliable phenotype predictor for HIV type 1 subtype C based on envelope V3 sequences. J Virol. 2006; 80:4698-4704.
15. Sing T, Beerenwinkel N, Lengauer T. Learning mixtures of localized rules by maximizing the area under the ROC curve. In: Hernández-Orallo J, Lachiche N, Flach P, eds. ROCAI- 2004 International Workshop on ROC Analysis in Artificial Intelligence. London, UK: Premiere Inc. 2004;89-96.
16. Berger E, Murphy P, Farber J. Chemokine receptors as HIV-1 coreceptors: role in viral entry, tropism, and disease. Annu Rev Immunol. 1999;17:657-700.
17. Kawamura T, Kurtz S, Blauvelt A. The role of Langerhans cells in the sexual transmission of HIV. J Dermatol Sci. 2005;40:147-155.
18. Bomsel M, David V. Mucosal gatekeepers: selecting HIV viruses for early infection. Nat Med. 2002;8:114-116.
19. Low A, Dong W, Chan D, et al. Current V3 genotypic algorithms are inadequate for predicting X4 co-receptor usage in clinical isolates. AIDS. 2007;21:F17-F24.
20. Wilkin T, Su Z, Kuritzkes D, et al. HIV-1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of CCR5 inhibitor: AIDS Clinical Trial Group A5211. Clin Infect Dis. 2007; 44:591-595.
21. Melby T, Despirito M, Demasi R, et al. HIV-1 coreceptor use in triple-class treatment-experienced patients: baseline prevalence, correlates, and relationship to enfuvirtide response. J Infect Dis. 2006;194:238-246.
22. Jensen M, van't Wout A. Predicting HIV-1 coreceptor usage with sequence analysis. AIDS Rev. 2003;5:104-112.
23. Karlsson I, Antonsson L, Shi Y, et al. HIV biological variability unveiled: frequent isolations and chimeric receptors reveal unprecedented variation of coreceptor use. AIDS. 2003;17:2561-2569.
24. Coakley E, Petropoulos C, Whitcomb J. Assessing chemokine co-receptor usage in HIV. Curr Opin Infect Dis. 2005;18:9-15.
25. Whitcomb J, Huang W, Fransen S, et al. Development and characterization of a novel single-cycle recombinant-virus assay to determine HIV-1 coreceptor tropism. Antimicrob Agents Chemother. 2007;51:566-575.
26. Melikyan G, Platt E, Kabat D. The role of the N-terminal segment of CCR5 in HIV-1 Env-mediated membrane fusion and the mechanism of virus adaptation to CCR5 lacking this segment. Retrovirology. 2007;4:55-62.
27. Walter BL, Wehrly K, Swanstrom R, et al. Role of low CD4 levels in the influence of HIV type 1 envelope V1 and V2 regions on entry and spread in macrophages. J Virol. 2005;79:4828-4837.
28. Skrabal K, Low A, Dong W, et al. Determining HIV coreceptor use in a clinical setting: degree of correlation between two phenotypic assays and a bioinformatic model. J Clin Microbiol. 2007;45:279-284.
29. Suphaphiphat P, Essex M, Lee TH. Mutations in the V3 stem versus the V3 crown and C4 region have different effects on the binding and fusion steps of HIV type 1 gp120 interaction with the CCR5 coreceptor. Virology. 2007;360:182-190.